Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

by Howell R, Wright AM, Clements JN
Published 2019

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes

by Gagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovich
Published 2017

Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?

by Khoury Johad, Andrawus Elias, Bishop Boaz Y., Azzam Zaher S.
Published 2018

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

by Pearson S, Kietsiriroje N, Ajjan RA
Published 2019

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes

by Nina A. Petunina, Milena Е. Telnova
Published 2018

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus

by Marina Vladimirovna Shestakova
Published 2010

Elevated Glucagon-like Peptide-1 and a Th2 Shift May Support Reduced Prevalence of Thoracic Aortic Aneurysm in Patients with Diabetes

by Stelia Ntika, Harshitha Jois, Karin Lång, Christian Olsson, Anders Franco-Cereceda, Hanna M. Björck, Camilla Krizhanovskii
Published 2021

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

by Knop FK, Hansen K, Knop FK
Published 2010

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day

by Igor A. Sklyanik, Marina V. Shestakova
Published 2021

Incretins today: multiple effects and therapeutic potential

by Oksana V. Tsygankova, Varvara V. Veretyuk, Alexander S. Ametov
Published 2019

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies

by Marina V. Shestakova, Ekaterina A. Yudovich
Published 2017

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

by Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova
Published 2020

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection

by Elena Nikolaevna Trunina, Nina Alexandrovna Petunina, Svetlana Alekseevna Chorbinskaya
Published 2011

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

by Ahren B
Published 2010

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice

by Lee J, Cho YK, Kim HS, Jung CH, Park JY, Lee WJ
Published 2019

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

by Yang P, Liang Y, Luo Y, Li Z, Wen Y, Shen J, Li R, Zheng H, Gu HF, Xia N
Published 2019

The associations of incretin hormone concentration with gestational diabetes mellitus

by Tatiana V. Saprina, Ekaterina S. Timokhina, Olga K. Goncharevich, Svetlana V. Budeeva, Tatiana S. Prokhorenko, Lyubov A. Tashireva, Nadezhda N. Musina, Irina V. Dronova
Published 2016

Incretin-based therapy: renal effects

by Anton Ivanovich Korbut, Vadim Valerievich Klimontov
Published 2016

Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko?

by Andrey Alexeevich Aleksandrov
Published 2011

Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment

by Li C, Wan L, Luo J, Jiang M, Wang K
Published 2021